Home LiteratureArticle Details
PMID: 9529315 Published · ppublish English Journal Article

Chronic inflammation and susceptibility to bacterial infections in mice lacking the polypeptide (p)105 precursor (NF-kappaB1) but expressing p50.

The Journal of experimental medicine ·Vol. 187 ·No. 7 ·1998-04-06 ·Pages 985-96

Ishikawa H, Claudio E, Dambach D, Raventós-Suárez C, Ryan C, Bravo R

Abstract

The polypeptide (p)50 molecule, a subunit of nuclear factor (NF)-kappaB, is produced after proteolytic processing of the p105 precursor (NF-kappaB1). Although the p105 precursor has been postulated to play a role in the regulation of the Rel/NF-kappaB activity, its physiological relevance remains unclear. To investigate that, we generated mutant mice lacking the COOH terminal half of the p105 precursor, but expressing the p50 product (p105-/-). These mutant mice displayed an inflammatory phenotype composed of lymphocytic infiltration in lungs and liver, and an increased susceptibility to opportunistic infections. Enlargement of multiple lymph nodes, splenomegaly due to erythrocytic extramedullary hematopoiesis, and lymphoid hyperplasia were also observed in p105-/- mice. Cytokine production in p105-/- macrophages was severely impaired, whereas proliferative responses of p105-/- B cells were increased. T cell functions were only moderately impaired in mutant mice. Loss of p105 also led to enhanced constitutive p50 homodimer and inducible NF-kappaB activities in unstimulated and stimulated cells, respectively. As several genes regulated by Rel/NF-kappaB were upregulated in p105-/- thymus but downregulated in p105-/- macrophages, the enhanced p50 homodimers appear to function as transcriptional activators or repressors, depending on the cell type. Thus, the p105 precursor is indispensable in the control of p50 activity, and lack of the precursor has distinct effects on different cells.

MeSH Terms
Animals Cytokines/metabolism Dimerization Flow Cytometry Gene Targeting Hematopoiesis/physiology Immunoglobulin G/blood Inflammation/metabolism Liver/pathology Lung/pathology Lymph Nodes/pathology Lymphocytes/metabolism Macrophages/metabolism Mice Mice, Knockout NF-kappa B/genetics,metabolism,physiology NF-kappa B p50 Subunit Opportunistic Infections/microbiology Protein Precursors/genetics,physiology Spleen/pathology Thymus Gland/metabolism
Chemicals
Cytokines Immunoglobulin G NF-kappa B NF-kappa B p50 Subunit Protein Precursors
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Ishikawa H
Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA.
Claudio E
Dambach D
Raventós-Suárez C
Ryan C
Bravo R
References (52)
52 references, click to expand
  1. Function and activation of NF-kappa B in the immune system.
    Annu Rev Immunol. 1994;12:141-79 PMID: 8011280
  2. The I kappa B proteins: members of a multifunctional family.
    Trends Genet. 1993 Dec;9(12):427-33 PMID: 8122310
  3. The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice.
    EMBO J. 1996 Jul 15;15(14):3640-50 PMID: 8670867
  4. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells.
    Nucleic Acids Res. 1989 Aug 11;17(15):6419 PMID: 2771659
  5. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation.
    Genes Dev. 1995 Nov 15;9(22):2723-35 PMID: 7590248
  6. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB.
    Nature. 1997 Aug 7;388(6642):548-54 PMID: 9252186
  7. Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-kappaB2.
    J Exp Med. 1997 Oct 6;186(7):999-1014 PMID: 9314550
  8. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B.
    Nature. 1995 Jul 13;376(6536):167-70 PMID: 7603567
  9. IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice.
    Mol Cell Biol. 1996 May;16(5):2341-9 PMID: 8628301
  10. Developmental expression of the mouse c-rel proto-oncogene in hematopoietic organs.
    Development. 1994 Oct;120(10):2991-3004 PMID: 7607087
  11. Independent modes of transcriptional activation by the p50 and p65 subunits of NF-kappa B.
    Genes Dev. 1992 May;6(5):775-87 PMID: 1577272
  12. I kappa B gamma, a 70 kd protein identical to the C-terminal half of p110 NF-kappa B: a new member of the I kappa B family.
    Cell. 1992 Mar 20;68(6):1109-20 PMID: 1339305
  13. Characterization of ES cells deficient for the p105 precursor (NF-kappa B1): role of p50 NLS.
    Oncogene. 1996 Jul 18;13(2):255-63 PMID: 8710364
  14. B cells from p50/NF-kappa B knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching.
    J Immunol. 1996 Jan 1;156(1):183-91 PMID: 8598461
  15. Structure, regulation and function of NF-kappa B.
    Annu Rev Cell Biol. 1994;10:405-55 PMID: 7888182
  16. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis.
    Science. 1994 Apr 29;264(5159):713-6 PMID: 8171324
  17. I kappa B epsilon, a novel member of the I kappa B family, controls RelA and cRel NF-kappa B activity.
    EMBO J. 1997 Mar 17;16(6):1413-26 PMID: 9135156
  18. Constitutive and inducible Rel/NF-kappa B activities in mouse thymus and spleen.
    Oncogene. 1994 Nov;9(11):3289-97 PMID: 7936653
  19. Regulation of the NF-kappa B/rel transcription factor and I kappa B inhibitor system.
    Curr Opin Cell Biol. 1993 Jun;5(3):477-87 PMID: 8352966
  20. Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers.
    Science. 1996 Mar 1;271(5253):1289-91 PMID: 8638112
  21. Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha.
    Cell. 1996 Sep 6;86(5):787-98 PMID: 8797825
  22. The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors.
    Genes Dev. 1993 Nov;7(11):2064-70 PMID: 8224838
  23. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice.
    Genes Dev. 1995 Nov 15;9(22):2736-46 PMID: 7590249
  24. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers.
    Genes Dev. 1993 Jul;7(7B):1354-63 PMID: 8330739
  25. Rel/NF-kappa B/I kappa B story.
    Adv Cancer Res. 1995;66:255-92 PMID: 7793317
  26. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers.
    Cell. 1993 Mar 12;72(5):729-39 PMID: 8453667
  27. Distinct NF-kappa B/Rel transcription factors are responsible for tissue-specific and inducible gene activation.
    Nature. 1993 Oct 21;365(6448):767-70 PMID: 7692309
  28. Transcriptional regulation of the HIV-1 promoter by NF-kappa B in vitro.
    Genes Dev. 1992 May;6(5):761-74 PMID: 1577271
  29. Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity.
    Cell. 1996 Mar 22;84(6):853-62 PMID: 8601309
  30. NF-kappa B and rel proteins in innate immunity.
    Adv Immunol. 1995;58:1-27 PMID: 7741027
  31. Overexpression of RelA in transgenic mouse thymocytes: specific increase in levels of the inhibitor protein I kappa B alpha.
    Mol Cell Biol. 1995 Jul;15(7):3523-30 PMID: 7791759
  32. Molecular mechanisms of TNFalpha cytotoxicity: activation of NF-kappaB and nuclear translocation.
    Exp Cell Res. 1996 Apr 10;224(1):63-71 PMID: 8612692
  33. Differential interactions of Rel-NF-kappa B complexes with I kappa B alpha determine pools of constitutive and inducible NF-kappa B activity.
    EMBO J. 1994 Oct 3;13(19):4608-16 PMID: 7925301
  34. The NF-kappa B p50 precursor, p105, contains an internal I kappa B-like inhibitor that preferentially inhibits p50.
    EMBO J. 1992 Aug;11(8):3003-9 PMID: 1639070
  35. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family.
    Cell. 1995 Jan 27;80(2):331-40 PMID: 7834753
  36. Functional and molecular characterization of single, (4-hydroxy-3-nitrophenyl)acetyl (NP)-specific, IgG1+ B cells from antibody-secreting and memory B cell pathways in the C57BL/6 immune response to NP.
    Eur J Immunol. 1992 Nov;22(11):3001-11 PMID: 1425924
  37. The precursor of NF-kappa B p50 has I kappa B-like functions.
    Cell. 1992 Oct 16;71(2):243-53 PMID: 1423592
  38. p105 and p98 precursor proteins play an active role in NF-kappa B-mediated signal transduction.
    Genes Dev. 1993 Apr;7(4):705-18 PMID: 8458581
  39. Expression of relB is required for the development of thymic medulla and dendritic cells.
    Nature. 1995 Feb 9;373(6514):531-6 PMID: 7845467
  40. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression.
    Genes Dev. 1995 Aug 15;9(16):1965-77 PMID: 7649478
  41. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B.
    Cell. 1994 Sep 9;78(5):773-85 PMID: 8087845
  42. Autoregulation of the NF-kappa B transactivator RelA (p65) by multiple cytoplasmic inhibitors containing ankyrin motifs.
    Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1346-50 PMID: 8108414
  43. NF-kappa B and Rel: participants in a multiform transcriptional regulatory system.
    Int Rev Cytol. 1993;143:1-62 PMID: 8449662
  44. Expression of relB transcripts during lymphoid organ development: specific expression in dendritic antigen-presenting cells.
    Development. 1993 Aug;118(4):1221-31 PMID: 8269849
  45. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses.
    Cell. 1995 Jan 27;80(2):321-30 PMID: 7834752
  46. The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa B.
    EMBO J. 1993 Jan;12(1):213-22 PMID: 8428580
  47. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway.
    Genes Dev. 1995 Jul 1;9(13):1586-97 PMID: 7628694
  48. Immunological defects in mice with a targeted disruption in Bcl-3.
    Genes Dev. 1997 Jan 15;11(2):187-97 PMID: 9009202
  49. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene.
    Cell. 1993 Oct 22;75(2):253-61 PMID: 8402910
  50. Mechanistic aspects of NF-kappa B regulation: the emerging role of phosphorylation and proteolysis.
    Immunity. 1995 Sep;3(3):263-72 PMID: 7552992
  51. Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions.
    Immunity. 1997 Apr;6(4):479-90 PMID: 9133427
  52. NF-kappa B: a lesson in family values.
    Cell. 1995 Feb 24;80(4):529-32 PMID: 7867060
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
1998-04-06
Pages
985-96
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2212206
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com